HomeAdvanced Structural Intervention Scores › Cryo vs RF Efficacy Model (AF Ablation) Calculator

Cryo vs RF Efficacy Model (AF Ablation) Calculator

  • Age (years)
  • AF Type
  • Left Atrial Diameter (mm)
  • Estimated GFR (ml/min/1.73 m2)
  • Left Ventricular Ejection Fraction (%)
  • Cryo vs RF Efficacy Model: Explanation and Clinical Context
    This calculator estimates the probability of remaining free from atrial tachyarrhythmia about 12 months after a single catheter ablation procedure and compares cryoballoon ablation (Cryo) with radiofrequency ablation (RF). It uses the validated APPLE score (Age > 65 years, persistent AF, eGFR < 60 ml/min/1.73 m2, left atrial diameter ≥ 43 mm, and LVEF < 50%) to predict baseline recurrence risk. Recurrence rates are based on published APPLE cohorts: 19% (score 0), 28% (1), 39% (2), and 52% (≥3). Since large randomized trials and meta-analyses demonstrate noninferior and equivalent efficacy between Cryo and RF for first-line PVI, both modalities are modeled as having similar outcomes.

    Normal/Expected Values
    Typical single-procedure arrhythmia-free rates at 1 year are 65–75% for paroxysmal AF, and lower for persistent AF.

    Clinical Significance
    The APPLE score allows quick pre-procedural estimation of recurrence risk, applicable to both Cryo and RF. It helps guide patient counseling, follow-up planning, and strategy optimization.

    Clinical Interpretation Summary
    Use the APPLE-based recurrence probability to tailor expectations and management. Expect similar efficacy for Cryo and RF; modality choice should instead consider anatomy, operator experience, and safety nuances.

    Reference:
    Kornej J, et al. Clin Res Cardiol. 2015;104:871–876.
    Kornej J, et al. Sci Rep. 2017;7:40828.
    Kuck KH, et al. FIRE AND ICE. N Engl J Med. 2016;374:2235–2245.
    Andrade JG, et al. CIRCA-DOSE. Circulation. 2019;140:1776–1784.
    Miyamoto K, et al. Eur Heart J. 2025 (advance).
    Kueffer T, et al. Heart Rhythm. 2024.
    Gao YM, et al. Eur J Med Res. 2025.